JAX Antibody Development Summit - Danying Cai

June 29, 2021

Dr. Danyig Cai, Associate Director, Innovation & Product Development, The Jackson Laboratory, presents An In Vivo PBMC Humanized Mouse Model for Determining Immunotherapy Related Cytokine Release Syndrome as part of The Jackson Laboratory's Antibody Drug Development Summit.

JAX Antibody Development Summit - Danying Cai

Cancer immunotherapy: getting a little help from ourselves

Comparing Immune-Humanized Mouse Platforms for Preclinical Applications

Comparing Immunodeficient Models for Cancer, Immunity, and Transplant Research

New Immune-humanized Models Support More Diverse Human Immune Cell Lineages

The Promise of Cancer Genomics

Exploring Cancer Research: Tools and Technologies

Leveraging Gene Therapy to Achieve Long-Term Continuous or Controllable Expression of Biotherapeutics

JAX Clinical Knowledgebase - Identify Resistance Variants in Preclinical Drug Testing

Making a Case for Preclinical Data - The JAX Clinical Knowledgebase

A Novel In Vivo Model to Simultaneously Assess Efficacy and Toxicity of Chimeric Antigen Receptor T-Cell Immunotherapy

Exploring Cancer: Biology and Inheritance

Immune-Humanized PDX Model-Estrogen-Independent, Hormone Receptor-Positive Metastatic Breast Cancer

Predictive Pre Clinical Oncology Studies Using Patient-Derived Xenograft Platforms

How To Make Your New NSG Variant in a Fraction of the Time

Achieving Relevant Preclinical Characterization of CAR T Cell Therapies

Designing Your In Vivo Studies

JAX Tech Talk Episode 48: Developing Immunotherapies with Hu-NSG-MHC I/II DKO Mice (Jan. 11, 2022)

JAX Tech Talk Episode 47: Let’s Talk Navigating the JAX Clinical Knowledgebase (Dec. 14, 2021)

Introduction to In Vivo Platforms for Cancer Immunotherapy

Human KIT+ Myeloid Cells Facilitate Visceral Metastasis By Melanoma